OncoCyte (NASDAQ:OCX) reported quarterly losses of $(1.13) per share which missed the analyst consensus estimate of $(0.67) by 68.66 percent. This is a 237.8 percent decrease over earnings of $0.82 per share from the same period last year. The company reported quarterly sales of $176.000 thousand which missed the analyst consensus estimate of $350.000 thousand by 49.71 percent. This is a 40.74 percent decrease over sales of $297.000 thousand the same period last year.